Yazılar

U.S. FDA to Roll Out AI Tools Across All Centers Following Successful Pilot

/in /tarafından

The U.S. Food and Drug Administration (FDA) announced it will immediately begin deploying artificial intelligence tools internally across all of its centers, with full integration expected by June 30. The move follows a successful generative AI pilot aimed at supporting scientific reviewers in accelerating the drug review process.

WHY IT MATTERS:
The FDA typically has 6 to 10 months to evaluate a drug approval application. The newly tested generative AI tools are designed to ease the burden on scientists by automating repetitive and time-consuming tasks, thereby streamlining the overall review process and potentially speeding up access to life-saving treatments.

In a statement, the agency emphasized that the focus of future AI enhancements would be on usability, better document integration, and center-specific output customization — all while upholding strict data security and FDA compliance standards.

KEY QUOTE:
“Future enhancements will focus on improving usability, expanding document integration and tailoring outputs to center-specific needs, while maintaining strict information security and compliance with FDA policy,” the FDA said.

CONTEXT:
The announcement comes just a day after Wired reported that the FDA had been in discussions with OpenAI, the maker of ChatGPT, regarding potential AI collaborations. The report also mentioned that representatives from Elon Musk’s Department of Government Efficiency had attended multiple meetings with both the FDA and OpenAI in recent weeks.

WHAT’S NEXT:
The FDA plans to monitor the system’s performance closely, solicit feedback from its users, and refine the tools accordingly. The agency has committed to releasing more information about the AI implementation and its outcomes in June.

This marks one of the most significant government-level adoptions of generative AI to date and could signal a broader shift toward AI-assisted regulatory workflows in the healthcare and pharmaceutical sectors.

FDA Rejects MDMA as PTSD Treatment Due to Insufficient Data

/in /tarafından

The U.S. Food and Drug Administration (FDA) has denied approval for the use of MDMA, a psychedelic drug commonly known as ecstasy or molly, for treating post-traumatic stress disorder (PTSD). The drug, developed by Lykos Therapeutics, was intended to be used in combination with talk therapy to help individuals suffering from PTSD. However, the FDA raised concerns about the limited clinical data provided, particularly questioning whether psychotherapy contributes to the drug’s effectiveness and whether it is necessary.

The FDA emphasized that the lack of sufficient data prevented them from determining that the drug is both safe and effective for its proposed use. The agency’s decision was influenced by an earlier vote from an expert panel, where the majority expressed doubts about the drug’s overall benefits. In a June panel, 10 out of 11 FDA advisers voted against the effectiveness of MDMA in treating PTSD, citing issues such as the potential lack of long-term benefits, the design of the studies, and the risks associated with heart problems, injury, and abuse.

Lykos Therapeutics expressed disappointment over the FDA’s decision, noting that additional research could take years to complete. The company highlighted the frustration of millions of Americans with PTSD who have seen few new treatment options in over two decades. Despite the setback, Lykos Therapeutics plans to continue working with the FDA to address the agency’s concerns.

This is the first time the FDA has considered a psychedelic drug for medical use. Currently, MDMA remains classified as a Schedule I drug under the Controlled Substances Act, alongside substances like cocaine, heroin, and cannabis, which are defined as having no accepted medical use and a high potential for abuse.